LeadingBiotech: Cancer Advance is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Pamela Contag, Ph.D.
Chief Executive Officer at BioEclipse Therapeutics


Dr. Contag is the CEO of BioEclipse Therapeutics and is an experienced senior executive for both public (President and CEO, Xenogen Corp., NASDAQ:XGEN), and multiple private companies including, most recently Cobalt Technologies and currently BioEclipse Therapeutics. BioEclipse is an early stage therapeutic company with technology from Stanford University, a combined immune cell/oncolytic virus immunotherapy for the treatment of solid tumors. As CEO of BioEclipse she was named in the top 100 most intriguing entrepreneurs of 2018 by Goldman Sachs.

Dr. Contag has extensive experience leading science and business teams for pioneering biomedical technology companies. She has served companies developing therapeutics and therapeutic platforms from early in her career to today, including Microcide Pharmaceuticals, Xenogen, Origin Therapeutics, Delcath Inc, and Epibiome. While serving as CEO of Xenogen, in 2000, Xenogen was listed as one of the "Top 25 Businesses" by Fortune Small Business and in both 2001 and 2003 the company received the R&D 100 award for achievements in Physics. In 2004, Xenogen was named as one of the top 100 fastest growing companies by the San Francisco Times, received the Frost and Sullivan Technology Innovations award, and the company completed a successful initial public offering (NASDAQ:XGEN). Dr. Contag was named one of the "Top 25 Women in Small Business" by Fortune magazine. She was also awarded the Northstar Award from Springboard Enterprises. While serving as CEO & Chairman of Cobalt Technologies, the company was named one of the top 20 cleantech companies. In 2011, Dr. Contag was awarded "Cleantech Innovator of the Year" award for technology developed at Cygnet Biofuels.

Previous board experience includes Xenogen Corp, Nasdaq; Delcath Inc, Nasdaq; Marrone BioInnovations, Nasdaq. Her corporate officer experience includes CEO and President of Xenogen Corporation Nasdaq. Xenogen Corporation, She was CEO and President of Cobalt Technologies, CEO of Contag Technologies, a company that consults in business and corporate development and develops platforms in therapeutics, biomass and biofuels; CSO of Origen Therapeutics, a platform antibody company.

In 2009, Pamela was appointed by the DOE to the Biomass Advisory Committee and in 2014, Chaired that committee. In 2011, Pam was appointed by the White House to the Founding Board of the Startup America Partnership, an organization envisioned by the Case and Kauffman Foundations and The White House to identify, encourage and celebrate all entrepreneurs. Pamela was a National Director of Springboard Enterprises, a National Business Accelerator, and a Scientific Advisor to Epibiome, a company with novel technology for treating infectious diseases with bacteriophage, and a Trustee for the Molecular Sciences Institute, a Research Institute founded by Nobel Laureate Sidney Brenner.

She received her M.S. in 1985 and PhD in1989 from the University of Minnesota Medical School in Microbiology and Immunology and completed her Postdoctoral Fellowship in 1993 at the Stanford University School of Medicine In the Falkow Laboratory studying host pathogen interactins. Her scientific expertise is in oncology and infectious diseases; the microbiology of anaerobes and the microbiology and Immunology of cancer and GI infectious diseases. With over 60 publications and 40 patents, Pam is active in both the scientific and entrepreneurial communities.

Pamela Contag, Ph.D.'s Network

Agenda Sessions

  • Therapeutic Market Focus: Immuno-Oncology